This Month in Psychopharmacology

THIS MONTH IN
PSYCHOPHARMACOLOGY

Browsing articles in "Psychotic Disorders"

Antipsychotic Use in Intellectually Disabled Adults
September 1, 2017

Antipsychotic medication is frequently being prescribed to individuals with intellectual and developmental disabilities (IDD), often without a psychiatric diagnosis...

Continue reading (Members only)

Deutetrabenazine Approved to Treat Tardive Dyskinesia
August 30, 2017

The U.S. Food and Drug Administration (FDA) has approved deutetrabenazine, trade name Austedo, for the treatment of tardive dyskinesia...

Non-Dopaminergic Drug Shows Efficacy in Reducing Negative Symptoms of Schizophrenia
August 13, 2017

A recent study examined the efficacy, safety, and tolerability of the compound, MIN-101 compared to placebo in patients with schizophrenia...

Continue reading (Members only)

Cannabis Use, Medication Non-Adherence, and Psychosis Relapse
August 4, 2017

New research shows that cannabis use by patients with psychosis is linked to a significantly increased risk for psychosis relapse. That increase in risk for relapse may be directly due to non-adherence to antipsychotic medication...

Continue reading (Members only)

Adverse Events and Limited Efficacy for Antipsychotics in Pediatric Psychosis
July 14, 2017

The treatment of psychosis in children and adolescents is perhaps more complicated and certainly less studied compared to psychosis in the adult population...

Continue reading (Members only)

What's New in Tardive Dyskinesia?
June 30, 2017

Tardive dyskinesia was the focus of several sessions, lectures, and posters at the recent 2017 American Psychiatric Association (APA) Annual Meeting...

Continue reading (Members only)

Recall: Paliperidone Extended-Release Tablets
June 16, 2017

Teva Pharmaceuticals has issued a voluntary recall of a single lot of paliperidone extended-release tablets...

Continue reading (Members only)

Highlights from the 2017 APA Annual Meeting
June 8, 2017

The 2017 APA annual meeting, held in NEI's hometown of San Diego, was themed "Prevention Through Partnership" and included more than 400 sessions. Here, we provide highlights of the meeting, including NEI's podcast interviews with expert presenters, key research from the poster sessions, and NEI's debut live concert--the NEI PsychopharmaJam.

2-Month Dose of Injectable Atypical Antipsychotic Approved
June 6, 2017

The U.S. Food and Drug Administration (FDA) has approved a new 2-month dose of an extended-release injectable atypical antipsychotic...

Continue reading (Members only)

No Evidence for Negative Long-Term Effect of Antipsychotic Treatment in Schizophrenia
May 17, 2017

Although antipsychotics have established efficacy for the acute control of positive symptoms of psychosis, there has been concern that the long-term use of these agents may have negative neurological consequences, such as reduced brain volume and sensitization of dopamine receptors...

Continue reading (Members only)

Top of Page